September 2021—Biocept announced a collaboration with Quest Diagnostics to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid-biopsy–targeted lung cancer panel.
Read More »Medicare issues LCD for Biocept’s Target Selector assay
September 2021—Biocept received a positive final local coverage determination that expands Medicare coverage for use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells. The coverage determination from the Centers for Medicare and Medicaid Services molecular diagnostics program was effective July 4.
Read More »Biocept, Quest to provide testing for lung cancer patients
June 23, 2021—Biocept announced a collaboration with Quest Diagnostics to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel.
Read More »Biocept, Protean BioDiagnostics establish research collaboration
June 2021—Biocept announced it will collaborate with Protean BioDiagnostics to research the ability of Biocept’s Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
Read More »Blood collection tubes for cfDNA, CTCs
July 2018—Biocept has launched its CEE-Sure blood collection tubes for research use only, and internationally distributed through VWR. CEE-Sure BCTs allow for the intact transport of liquid biopsy samples at room temperature.
Read More »Liquid biopsy PD-L1 test, 8/16
August 2016—Biocept launched its CLIA-validated PD-L1 protein expression test, which uses Biocept’s proprietary, patented Target Selector platform with circulating tumor cells from a patient’s blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient’s cancer therapy.
Read More »c-MET biomarker, 9/15
Biocept launched its c-MET amplification detection test. This diagnostic assay, which uses a blood-based liquid biopsy, has the potential to help physicians identify patients who may be receptive to certain gastric and non-small cell lung cancer treatments.
Read More »NSCLC blood-based liquid biopsy test
January 2015—Biocept launched its lung cancer liquid biopsy testing, performed at its CLIA-certified, CAP-accredited laboratory. The blood-based biomarker testing for non-small cell lung cancer, along with the previously commercialized breast cancer offering, provides options for health care professionals and researchers for when a tumor biopsy is not available or is unsafe to perform or when additional information is desired.
Read More »